Efficacy, safety, and impact of fluorescein in frameless stereotactic needle biopsies - a case series.
Biopsy
Fluorescence
Stereotatic techniques
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
received:
07
04
2024
accepted:
23
08
2024
revised:
27
06
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
epublish
Résumé
Stereotactic needle biopsy stands as a crucial method for diagnosing intracranial lesions unsuitable for surgical intervention. Nonetheless, the potential for sampling errors lead to innovative approaches to enhance diagnostic precision. This study contrasts the outcomes of patients undergoing fluorescein-assisted frameless stereotactic needle biopsy with those receiving traditional biopsies to evaluate the impact on diagnostic accuracy and safety. This study included patients with contrast-enhancing intracranial lesions, comprising a prospective group undergoing fluorescein-assisted biopsies and a retrospective group undergoing conventional biopsies at the same institution. We've collected data on demographics, procedural specifics, diagnostic outcomes, and postoperative events. A comparative analysis involved 43 patients who received fluorescein-assisted biopsies against 77 patients who underwent conventional biopsies. The average age was 60.5 years. The fluorescein group exhibited a 93% success rate in diagnosis, markedly higher than the 70.1% in the non-fluorescein group (OR = 5.67; 95%IC: 1.59-20.24; p < 0.01). The rate of complications was statistically similar across both cohorts. Despite its established value, stereotactic needle biopsy is susceptible to inaccuracies and complications. The application of fluorescence-based adjuncts like 5-ALA and fluorescein has been investigated to improve diagnostic fidelity and reduce risks. These technologies potentially minimize the necessity for multiple biopsies, decrease surgical duration, and provide immediate verification of tumor presence. Fluorescein-assisted stereotactic biopsy emerges as an effective, secure alternative to conventional methods.
Identifiants
pubmed: 39223420
doi: 10.1007/s10143-024-02758-6
pii: 10.1007/s10143-024-02758-6
doi:
Substances chimiques
Fluorescein
TPY09G7XIR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
523Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Lobato RD, Rivas JJ, Cabello A, Roger R (1982) Stereotactic biopsy of Brain lesions visualized with computed tomography. Stereotact Funct Neurosurg 45(4–5):426–430. https://doi.org/10.1159/000101637
doi: 10.1159/000101637
Braga HM, Dellaretti MA, Faria MP, Almeida JCD, Nascimento LMD (2023) Accuracy comparison between Frameless Biopsy and Frame-based biopsy: a retrospective study of a Case Series. Arq Bras Neurocir Braz Neurosurg 42(03):e233–e238. https://doi.org/10.1055/s-0043-1775556
doi: 10.1055/s-0043-1775556
Parney IF, Berger MS (2012) Principles of brain tumor surgery. Handbook of clinical neurology, vol 104. Elsevier, pp 187–213. doi: https://doi.org/10.1016/B978-0-444-52138-5.00015-3
Dellaretti M, Reyns N, Touzet G et al (2012) Stereotactic biopsy for Brainstem tumors: comparison of Transcerebellar with Transfrontal Approach. Stereotact Funct Neurosurg 90(2):79–83. https://doi.org/10.1159/000335502
doi: 10.1159/000335502
pubmed: 22286495
Jackson RJ, Fuller GN, Abi-Said D et al Limitations of stereotactic biopsy in the initial management of gliomas. Published online 2001.
Sawin P (1998) Computed imaging-assisted stereotactic brain biopsy a risk analysis of 225 consecutive cases. Surg Neurol 49(6):640–649. https://doi.org/10.1016/S0090-3019(97)00435-7
doi: 10.1016/S0090-3019(97)00435-7
pubmed: 9637625
Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD (2005) Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res 27(4):358–362. https://doi.org/10.1179/016164105X40057
doi: 10.1179/016164105X40057
pubmed: 15949232
Xu R, Rösler J, Teich W et al (2022) Correlation of Tumor Pathology with Fluorescein Uptake and MRI contrast-enhancement in stereotactic biopsies. J Clin Med 11(12):3330. https://doi.org/10.3390/jcm11123330
doi: 10.3390/jcm11123330
pubmed: 35743401
pmcid: 9225185
Falco J, Cavallo C, Vetrano IG et al (2019) Fluorescein Application in Cranial and spinal tumors enhancing at Preoperative MRI and operated with a dedicated filter on the Surgical microscope: preliminary results in 279 patients enrolled in the FLUOCERTUM prospective study. Front Surg 6:49. https://doi.org/10.3389/fsurg.2019.00049
doi: 10.3389/fsurg.2019.00049
pubmed: 31475153
pmcid: 6705221
Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L (2020) Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering Optical labels to Brain tumors. Front Oncol 10:739 Published 2020 Jun 5. https://doi.org/10.3389/fonc.2020.00739
doi: 10.3389/fonc.2020.00739
pubmed: 32582530
pmcid: 7290051
Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O’Neill N, for the PROCESS Group (2020). The PROCESS 2020 Guideline: updating Consensus Preferred reporting of CasE series in surgery (PROCESS) guidelines. Int J Surg ;60 (article in press).
Sun GW, Shook TL, Kay GL (1996) Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 49(8):907–916. https://doi.org/10.1016/0895-4356(96)00025-x
doi: 10.1016/0895-4356(96)00025-x
pubmed: 8699212
Shooman D, Belli A, Grundy PL (2010) Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination: clinical article. J Neurosurg 113(2):170–178. https://doi.org/10.3171/2009.12.JNS09573
doi: 10.3171/2009.12.JNS09573
pubmed: 20136389
Von Campe G, Moschopulos M, Hefti M (2012) 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence as immediate intraoperative indicator to improve the safety of malignant or high-grade brain tumor diagnosis in frameless stereotactic biopsies. Acta Neurochir (Wien) 154(4):585–588. https://doi.org/10.1007/s00701-012-1290-8
doi: 10.1007/s00701-012-1290-8
Rey-Dios R, Hattab EM, Cohen-Gadol AA (2014) Use of intraoperative fluorescein sodium fluorescence to improve the accuracy of tissue diagnosis during stereotactic needle biopsy of high-grade gliomas. Acta Neurochir (Wien) 156(6):1071–1075. https://doi.org/10.1007/s00701-014-2097-6
doi: 10.1007/s00701-014-2097-6
pubmed: 24770732
Widhalm G, Minchev G, Woehrer A et al (2012) Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurg Rev 35(3):381–391. https://doi.org/10.1007/s10143-012-0374-5
doi: 10.1007/s10143-012-0374-5
pubmed: 22407140
Moriuchi S, Yamada K, Dehara M et al (2011) Use of 5-aminolevulinic acid for the confirmation of deep-seated brain tumors during stereotactic biopsy: report of 2 cases. J Neurosurg 115(2):278–280. https://doi.org/10.3171/2011.4.JNS102137
doi: 10.3171/2011.4.JNS102137
pubmed: 21548751
Hefti M, Siegner A, Looser H, Von C (2008) 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery. Swiss Med Wkly Published Online March 22. https://doi.org/10.4414/smw.2008.12077
Hansen RW, Pedersen CB, Halle B et al (2020) Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study. J Neurosurg JNS 133(5):1324–1331. https://doi.org/10.3171/2019.6.JNS191531
doi: 10.3171/2019.6.JNS191531
Singh DK, Khan KA, Singh AK et al (2023) Fluorescein sodium fluorescence: role in stereotactic brain biopsy. Br J Neurosurg 37(1):82–85. https://doi.org/10.1080/02688697.2021.2016615
doi: 10.1080/02688697.2021.2016615
pubmed: 34927514
Thien A, Han JX, Kumar K et al (2018) Investigation of the usefulness of fluorescein sodium fluorescence in stereotactic brain biopsy. Acta Neurochir (Wien) 160(2):317–324. https://doi.org/10.1007/s00701-017-3429-0
doi: 10.1007/s00701-017-3429-0
pubmed: 29275519
Catapano G, Sgulò FG, Seneca V, Iorio G, De Notaris M, Di Nuzzo G (2019) Fluorescein-assisted stereotactic needle biopsy of brain tumors: a single-center experience and systematic review. Neurosurg Rev 42(2):309–318. https://doi.org/10.1007/s10143-018-0947-z
doi: 10.1007/s10143-018-0947-z
pubmed: 29383601